Compare GE Vernova Inc (GEV) vs Novartis AG (NVS) Price & Performance

GE Vernova (GEV) trades at $997.09, down 3.12% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical signals with support at $985 and resistance at $1,005. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed estimates. The company benefits from AI-driven power demand growth and secured the first US construction permit for its BWRX-300 small modular reactor.

GEV presents compelling growth potential driven by AI infrastructure demand and nuclear energy expansion, with revenue projected to grow from $38.1B to $41.4B. However, elevated valuation multiples (P/E 28.59, EV/EBITDA 85.02) and execution risks in the wind power segment warrant caution. The strong analyst consensus and 45% YTD gain suggest continued momentum if operational targets are met.

Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.

Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.